DE69939663D1 - Behandlung von morbus parkinson mit oligonukleotiden - Google Patents

Behandlung von morbus parkinson mit oligonukleotiden

Info

Publication number
DE69939663D1
DE69939663D1 DE69939663T DE69939663T DE69939663D1 DE 69939663 D1 DE69939663 D1 DE 69939663D1 DE 69939663 T DE69939663 T DE 69939663T DE 69939663 T DE69939663 T DE 69939663T DE 69939663 D1 DE69939663 D1 DE 69939663D1
Authority
DE
Germany
Prior art keywords
treatment
oligonucleotides
targeted
sub
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69939663T
Other languages
English (en)
Inventor
Jay S Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Application granted granted Critical
Publication of DE69939663D1 publication Critical patent/DE69939663D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152—Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69939663T 1998-11-05 1999-11-05 Behandlung von morbus parkinson mit oligonukleotiden Expired - Lifetime DE69939663D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10719198P 1998-11-05 1998-11-05
PCT/US1999/026128 WO2000025798A1 (en) 1998-11-05 1999-11-05 Treatment of parkinson's disease with oligonucleotides

Publications (1)

Publication Number Publication Date
DE69939663D1 true DE69939663D1 (de) 2008-11-13

Family

ID=22315323

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69939663T Expired - Lifetime DE69939663D1 (de) 1998-11-05 1999-11-05 Behandlung von morbus parkinson mit oligonukleotiden

Country Status (8)

Country Link
US (2) US20030060436A1 (de)
EP (1) EP1135113B1 (de)
JP (1) JP2002528509A (de)
AT (1) ATE409487T1 (de)
CA (1) CA2350212A1 (de)
DE (1) DE69939663D1 (de)
ES (1) ES2317710T3 (de)
WO (1) WO2000025798A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538145A (en) * 2002-08-07 2008-05-30 Univ Delaware Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
EP1428875B1 (de) * 2002-12-13 2006-06-28 Centre National De La Recherche Scientifique (Cnrs) Verfahren zur Diagnose von Fettsucht
KR100616742B1 (ko) * 2004-02-27 2006-08-28 한국원자력연구소 글루타메이트 디카르복실라제 67의 안티센스 유전자를유효성분으로 포함하는 항암제, 상기 유전자를 포함하는발현 벡터 및 이를 형질도입한 형질전환체
WO2006013457A2 (en) * 2004-03-19 2006-02-09 Diamyd Medical Ab Gad2 gene for possible treatment of nervous system disorders
TWI809004B (zh) * 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
WO2019140231A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
WO2022271938A1 (en) * 2021-06-23 2022-12-29 Enclear Therapies, Inc. Method of regulating gene expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU678769B2 (en) * 1992-07-27 1997-06-12 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US5929042A (en) * 1997-03-03 1999-07-27 The Trustees Of Columbia University In The City Of New York Antisense compounds which prevent cell death and uses thereof

Also Published As

Publication number Publication date
US20030060436A1 (en) 2003-03-27
US20050020530A1 (en) 2005-01-27
EP1135113B1 (de) 2008-10-01
US7414034B2 (en) 2008-08-19
EP1135113A1 (de) 2001-09-26
CA2350212A1 (en) 2000-05-11
JP2002528509A (ja) 2002-09-03
ATE409487T1 (de) 2008-10-15
ES2317710T3 (es) 2009-04-16
WO2000025798A1 (en) 2000-05-11
EP1135113A4 (de) 2004-12-22
WO2000025798A8 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
Wallace et al. The amygdalo-brainstem pathway: selective innervation of dopaminergic, noradrenergic and adrenergic cells in the rat
Zangen et al. Association between depressive behavior and absence of serotonin–dopamine interaction in the nucleus accumbens
Scharfman et al. Actions of brain-derived neurotrophic factor in slices from rats with spontaneous seizures and mossy fiber sprouting in the dentate gyrus
Nambu et al. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey
Sessle Neural mechanisms and pathways in craniofacial pain
RU2008121750A (ru) Ионофоретическая доставка ротиготина для лечения болезни паркинсона
US20190183824A1 (en) Use of pde7 inhibitors for the treatment of movement disorders
ATE409487T1 (de) Behandlung von morbus parkinson mit oligonukleotiden
WO1992011851A1 (en) Method and compositions for treatment of sexual impotence
WO2004089353A3 (en) Methods for treatment of parkinson's disease
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
HUP0102511A2 (hu) Kombinált gyógykezelés bipoláris betegségek kezelésére
Da Prada et al. The effect of 5, 6-dihydroxytryptamine on sexual behaviour of male rats
Duty et al. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
Hamani et al. Deep brain stimulation for the treatment of Parkinson’s disease
Gnanalingham et al. Chronic continuous and intermittentl-3, 4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6-hydroxydopamine lesioned rats—an autoradiographic study using [3H] flunitrazepam
Rodríguez-Manzo et al. Electrical stimulation of dorsal and ventral striatum differentially alters the copulatory behavior of male rats.
Faingold et al. Modulation of the audiogenic seizure network by noradrenergic and glutamatergic receptors of the deep layers of superior colliculus
Patz et al. Neurotrophins induce short‐term and long‐term changes of cortical neurotrophin expression
Delfs et al. Unilateral nigrostriatal lesions induce a bilateral increase in glutamate decar☐ ylase messenger rna in the reticular thalamic nucleus
Guo et al. The effect of electroacupuncture on spontaneous recurrent seizure and expression of GAD67 mRNA in dentate gyrus in a rat model of epilepsy
Lees Levodopa substitution: the gold standard
Ogura et al. The mechanism and effect of chronic electrical stimulation of the globus pallidus for treatment of Parkinson disease
JP2002528509A5 (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition